Active substance

Results for the substance ribociclib

2 results

About this active substance

Ribociclib is a medication used for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). It acts as an inhibitor of cyclin-dependent kinases (CDK4/6), slowing the growth of cancer cells.

The medication is taken orally, as directed by a doctor, usually once daily, in combination with other hormonal therapies. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor liver and hematologic function.

Patients should be aware of potential side effects, such as nausea, fatigue, or a decrease in white blood cell count. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, fatigue, and a decrease in white blood cell count. In rare cases, severe reactions such as hepatotoxicity or QT interval prolongation may occur. Patients should be informed of these risks before starting treatment.